Onxeo Announces the Evolution and Reinforcement of Its Board of Directors

  · Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari,
international expert in Oncology, join the Onxeo Board of Directors as Board
Observers
  · Joseph Zakrzewski elected as Onxeo Chairman
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, announced that Prof. Jean-Pierre Kinet, M.D., of Harvard Medical School,
and Jean-Pierre Bizzari, M.D., world-renowned experts in oncology with over 20
years of pharma and biotech experience in the United States, have been appointed
Observers to the Board of Directors, effective immediately. Their appointments
as full board members will be submitted to the shareholders during the next
annual shareholders meeting.

Dr. Bizzari has dedicated his professional life to clinical development,
especially in oncology, and has brought to the market several leading cancer
drugs – including ABRAXANE® (nab-paclitaxel), ELOXATIN® (oxaliplatin), and
TAXOTERE® (docetaxel). During his most recent experience as Executive Vice
-President of Clinical Oncology Development at Celgene, Dr. Bizzari developed
hematology and solid tumors therapeutics, including an HDAC inhibitor.

Dr. Kinet will bring to Onxeo his research expertise in immunology and oncology
acquired through various positions in academia, including his current position
as Professor of Pathology at Harvard Medical School (Boston - USA). Both will
provide Onxeo with access to a very valuable network of academic, biotech, and
pharma leaders in the United States and in Europe and will further enhance the
current high level of expertise of the company’s Board of Directors.

In addition, Mr. Joseph Zakrzewski has been elected Chairman of Onxeo’s Board of
Directors, as announced in October 2015. He is replacing Patrick Langlois, who
has resigned. Mr. Zakrzewski has more than 25 years of experience in the global
healthcare industry with a strong focus in the United States.

Joseph Zakrzewski commented: “We are proud to welcome Drs. Kinet and Bizzari to
our team. Their appointments will bring additional knowledge and expertise of
both research and clinical development in Oncology to the Board and Onxeo’s
teams, as we are leading our key compounds towards advanced clinical development
and expanding our research programs with preclinical experimentations. Their
experience and intimate knowledge of the academic and biotech fields and network
worldwide will be key strengths in growing the company through a strong and
powerful pipeline. The appointments of these two renowned and respected members
of the biopharma industry will strengthen our position as a leader in orphan
oncology research and development. I also would like to thank former Chairman
Patrick Langlois for his commitment to Onxeo’s development through its focus on
high potential orphan oncology products. Under his leadership, the company
underwent significant transformation, paving the way for it to become a key
player in the orphan oncology space. I am excited to join a company with such a
robust ambition as Onxeo.”

Jean-Pierre Bizzari, M.D., added: “Joining Onxeo’s Board of Directors is a real
opportunity to contribute to the development of breakthrough treatments in
orphan oncology. I am excited to offer my knowledge and experience in the
clinical development of anticancer agents to Onxeo’s promising pipeline.”

Prof. Jean-Pierre Kinet, M.D., stated: “With its two lead products under
development and an ambitious preclinical program, Onxeo can make a significant
contribution to R&D in the orphan oncology field. I am looking forward to
contributing to the reinforcement of Onxeo’s position in this field.”

Biographies:

JEAN-PIERRE BIZZARI, M.D., served as Executive Vice-President, Group Head, and
Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from
2008 to 2015. He has been involved in the clinical development of several
anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11).
As a world-renowned oncology expert, he is a member of the Scientific Advisory
Board of the French National Cancer Institute (INCa) and European Organization
of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug
Advisory Committee. Mr. Bizzari is also an active board member in various
biotech companies, such as Transgene in France, Halozyme Therapeutics and
Celator Pharmaceuticals in the US. He has published more than 70 articles in
peer-reviewed journals and more than 160 abstracts in scientific congresses.

Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the
Institut de Recherches Internationales SERVIER (France). He then joined Rhône
-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris
and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari
served as Vice President of Clinical Oncology Development at Sanofi-Aventis in
Malvern, PA before joining Celgene.

Jean-Pierre Bizzari holds a medical degree specialized in oncology from the
University of Nice (France) and has trained successively at the Pitié
-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac
Gill Cancer Center in Canada.

Prof. JEAN-PIERRE KINET, M.D., is one of the most prominent immunology experts
worldwide, most famous for discovering some of the genes and proteins
constituting the immunoglobulin E receptor. These scientific breakthroughs
contributed to the introduction of new diagnostic tools and therapies for
diseases related to immune system dysregulation. He also is the co-founder and
founder of two biotech companies (AB Science and Astarix), and is a board member
of several other biotech companies in Europe.

He is Professor of Pathology at Harvard Medical School (Boston - USA). He is
also a member of National Institute of Health (NIH) expert panels, and of the
medical Board of the American Asthma Foundation in the USA. Jean-Pierre Kinet is
a member of the Scientific Advisory Board of UCB Pharma and Managing Partner of
iXLife Capital. Jean-Pierre Kinet received his medical degree from the
University of Liege (Belgium), and was trained in internal medicine at the Liège
University hospital. He has written over 200 publications and holds 10 American
and global patents. In 1997, he received the NIH "Inventor Award" and in 2004
the prestigious "NIH Merit Award". He was decorated in 2000 as a Knight of the
National Order of Merit of the French Republic.

JOSEPH ZAKRZEWSKI has over 25 years of experience as an executive in the
biotechnology and pharmaceutical industry, serving on the Board of Directors of
publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals,
Insulet Corporation, and Onxeo. Mr. Zakrzewski also serves on the board of a
number of privately held companies, is advisor to a number of entities, and is
involved in a number of philanthropic activities. He was Chairman and CEO of
Amarin Pharmaceuticals, a publicly traded company focused on the development and
commercialization of cardiovascular drugs based on Omega 3‘s from 2010 through
2013 successfully developing and launching Vascepa®. Mr. Zakrzewski served as a
Venture Partner with Orbimed, the world’s largest healthcare-dedicated
investment firm in 2010 and 2011. Prior to this, he was Chairman, President and
Chief Executive Officer of Xcellerex, a privately held company focusing on
commercializing its proprietary next generation manufacturing technology for
biotherapeutics and vaccines from 2007 through 2010. Xcellerex was sold to GE
Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant
Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular
drugs from 2005 through 2007. Mr. Zakrzewski had responsibility for the
company’s pharmaceutical operations including R&D, business development, supply
chain and manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals
was sold to GlaxoSmithKline in 2007. From 1988 to 2004, Mr. Zakrzewski served in
a variety of executive level capacities at Eli Lilly & Company including R&D,
manufacturing, finance, and business development focused on Lilly’s
biotechnology and protein business. His most recent position was Vice President,
Corporate Business Development, where he had global responsibility for all
business development activities on a worldwide basis. A US citizen, Mr.
Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical
Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from
Indiana University.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™)
Validive® (Clonidine Lauriad®)
Beleodaq® (belinostat)
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51265794&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=de5e82116892dbcd203c11e0c8fe709f)

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51265794&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=4881332ea
8 
1ddd82df3bf4e714166e09)

Follow us on Twitter @Onxeo_

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51265794&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=2e8e37b2fdd08f36c332a867b7e483f4)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51265794&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=870dcc1087f1131b39f8a70a6446da07)).
Contacts

Onxeo
Investor Relations
Nathalie Delair-Trepo, + 33 1 45 58 76 00
investors@onxeo.com
or
Alize RP (France)
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1 508 280 6592 / +1 646 536 7012
kthomas@theruthgroup.com / lroth@theruthgroup.com